Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

118 results about "Human papilloma virus infection" patented technology

Preparation method for biological agent for preventing and controlling human papilloma virus infection

The invention discloses a preparation method for a biological agent for preventing and controlling human papilloma virus infection. The preparation method includes following steps: dissolving 3-hydroxy-phthalic anhydride HP into dimethyl sulfoxide DMSO to obtain saturated HP solution; dissolving beta-lactoglobulin beta-LG into 0.1M of sodium phosphate solution with pH (potential of hydrogen) of 8.5 to obtain protein solution with protein final concentration of 20mg / mL; and equally dividing the HP solution into five parts, adding the HP solution into the protein solution at every 12 minutes, shaking and mixing, adjusting pH of IMNaOH to be 8.5, leading the final concentration of anhydride in a reaction system to be 60mM, standing for 1 hour at the temperature of 25 DEG C, dialyzing by PBS (phosphate buffer solution) with pH of 7.4, performing filtration sterilization by a 0.45uM microfiltration membrane, and storing at the temperature of 4 DEG C so as to obtain a finished product. The biological agent has the advantages of capabilities of stopping HPV (human papilloma virus) from invading cells and stopping virus infection from spreading, safety, stability, low cost and the like.
Owner:SHANXI JINBO BIO PHARMA CO LTD

HPV antigens, vaccine compositions, and related methods

The present invention relates to the intersection of the fields of immunology and protein engineering, and particularly to antigens and vaccines useful in prevention of infection by human papilloma virus. Provided are recombinant protein antigens, compositions, and methods for the production and use of such antigens and vaccine compositions.
Owner:FRAUNHOFER USA

Human papilloma virus infection gene amplification fluorescent detection kit

The invention discloses a probe and a primer which have nucleotide sequence complementary with HPV DNA, wherein, the probe is selected from SEQ ID Nos: 1 to 13; the primer is selected from SEQ ID SEQ ID Nos: 14 to 39; the invention also discloses a fluorescence identification kit comprising the probe and the primer and used for indentifying nucleic acid amplification infected by high-risk human papillomavirus, which contains 13 varieties of high-risk human papillomavirus subtypes and can finish extracting and detecting 80 to 100 portions of clinical samples DNA in 3 hours. The invention has the advantages of high sensitivity and specificity and low price, thus being easy to be accepted by patients and easy for popularizing and spreading.
Owner:潮州凯普生物化学有限公司 +1

Bioprotein dressing and bioprotein invisible film for preventing and controlling human papilloma virus infection

The invention discloses a bioprotein dressing and a bioprotein invisible film for preventing and controlling human papilloma virus infection, relates to products for gynecological diseases and solves the problem of absence of medicines capable of effectively preventing and controlling HPV (human papilloma virus) infection in foreign and domestic markets. The bioprotein dressing comprises, by mass concentration, 0.05-1%o of JB protein, 1-3% of carbomer, 0.5-2% of green tea extracts, 1-5% of glycerol, 0.1-0.3% of triclosan and the balance water. The bioprotein invisible film comprises, by mass concentration, 0.05-1%o of JB protein, 0.05-1% of carbomer, 0.5-2% of green tea extracts, 1-5% of glycerol, 0.11-0.25% of enhanceparaben, 0.1-2% of phenoxyethanol and the balance water. The bioprotein dressing is anti-HPV biological agent, is good in biocompatibility, nonirritant, safe and free of side effect.
Owner:SHANXI JINBO BIO PHARMA CO LTD

Adenoviral Vector Vaccine

Provided are adenoviral vectors for generating an immune response to antigen. The vectors comprise a transcription unit encoding a secretable polypeptide, the polypeptide comprising a secretory signal sequence upstream of a tumor antigen upstream of CD40 ligand, which is missing all or substantially all of the transmembrane domain rendering CD40L secretable. Also provided are methods of generating an immune response against cells expressing a tumor antigen by administering an effective amount of the invention vector. Further provided are methods of generating an immune response against cancer expressing a tumor antigen in an individual by administering an effective amount of the invention vector. Still further provided are methods of generating immunity to infection by human papilloma virus (HPV) by administering an effective amount of the invention vector which enocodes the E6 or E7 protein of HPV. The immunity generated is long term.
Owner:VAXUM

Application of polypeptide in preparing preparations for preventing and treating human papilloma virus infection

The invention discloses an application of polypeptide in preparing preparations for preventing and treating human papilloma virus infection, and belongs to the field of infectious disease treatment. Apolypeptide preparation for preventing and treating human papilloma virus infection is also provided; and the polypeptide preparation takes the polypeptide with effective dose as active ingredients and is prepared by adding pharmaceutically acceptable subsidiary materials or auxiliary components. The polypeptide can be used for the treatment and prevention of human papilloma virus infection, so that the polypeptide is significant in effect; and the polypeptide has no inhibition effects on the normal flora of female genital tracts, so that the polypeptide is good in safety.
Owner:GENLOCI BIOTECH

Use of methyltestosterone as a drug for treatment of human papilloma virus infections

The present invention discloses the use of methyltestosterone as a novel pharmaceutical for treatment of anti-HPV infections, especially for treatment of verruca planae, condyloma acuminatum, and the relapse of these disorders. The therapeutic efficacy of the aforementioned indications proves satisfactory.
Owner:LIANG YOUGOU +2

Modification sequence of recombinant human mammilla tumor virus L1 capsid protein

InactiveCN101481407AStructural stability has no appreciable effectStructural Stability EffectsViral antigen ingredientsAntiviralsAntigenHuman papillomavirus
The invention relates to the prevention and treatment field of human papillomavirus infection, in particular to an amino acid modification sequence of recombinant human papillomavirus (HPV) L1 capsid protein, a nucleotide sequence encoding the amino acid modification sequence, and a carrier and a transformant containing the nucleotide sequence; and the invention further relates to application of an HPV L1 protein polymer consisting of the amino acid modification sequence to preparing vaccines, pharmaceutical compositions and diagnostic antigen or diagnostic antibodies. In the invention, an HPV L1 protein wild-type sequence is modified to prevent forming of a disulfide bond in the HPV L1 protein, the modification has no significant effect on the structural stability of the recombinant HPV L1 protein, but significantly improves the efficiency of purification process, and directly reduces the reagent consumption, thus effectively lowering the industrial production cost and having great economical benefit.
Owner:马润林 +1

HPV DNA Vaccines and Methods of Use Thereof

InactiveUS20080260765A1Enhance antigen-specific immune responseEnhance immune responseSugar derivativesViral antigen ingredientsDiseaseTreatment effect
Human papillomavirus (HPV) infection is the etiological factor for cervical cancer. Provided are HPV vaccines that generate a humoral immune response to prevent new infection, as well as cell-mediated immunotherapy to eliminate established infection or HPV-related disease. HPV vaccines include nucleic acid sequences encoding HPV16 early proteins E6 and E7. Additional nucleic acid sequences in the vaccines include sequences encoding calreticulin and / or the HPV16 late protein L2. Methods using these vaccines are provided that result in therapeutic effects.
Owner:THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE

Method for treating cervical cancer

Use of Interleukin-20 for treating cervical cancer or cells infected with human papilloma virus. IL-20 can be administered alone or in conjunction with radiation or chemotherapeutic agents or surgical excision of the involved cells or lesions.
Owner:ZYMOGENETICS INC

Topical treatment of skin disease and eye afflictions

A method of treating patients having viral infections including herpes simplex virus 1 and 2 infections and human papillomavirus infections by topically administering Product R, a peptide-nucleic acid preparation, by itself or in a composition comprising Product R and other pharmaceutically acceptable carriers for topical administration, is disclosed.
Owner:BBM HLDG

Compound vaccine composition for preventing and controlling human viral infection, compound vaccine vaginal mist and uses thereof

The invention relates to a compound vaccine composition for preventing and treating human papillomavirus infection, a compound vaccine vaginal spray and uses thereof, and belongs to the field of vaccine preparations with targeted treatment indications. The product of the present invention can prevent cervical cancer and treat HPV infection; it is suitable for married women of any age; it can prevent and treat chronic cervicitis and cervical epithelial dysplasia caused by sexually transmitted HPV infection, including CIN I, II, III Degree, inhibit HPV reproduction, prevent cervical cancer.
Owner:北京金迪克生物技术有限责任公司

Charge modified lactoferrin and carrageenin combination medicine and preparation method thereof

The invention discloses a charge modified lactoferrin and carrageenin combination medicine which comprises 0.01 part by weight of lactoferrin, 1.5 parts by weight of carrageenin, 5 parts by weight of carbomer, 50 parts by weight of glycerol and 0.1 part by weight of ethylparaben. The combination medicine is one of a gel, a suppository and a dressing. The combination medicine disclosed by the invention can be used for preventing and treating female human papilloma virus infection as well as preventing and treating female gynecological gram-negative bacterium infection.
Owner:NANJING LAKESEN BIOPHARM TECH CO LTD

Traditional Chinese medicine used for treating human papillomavirus infection

A Chinese medicine for treating the human papillomavirus infection and clearing the papillomavirus from human body is prepared from safflower and scouring herb.
Owner:杭州清净和生物工程有限公司

Anti-HPV (human papilloma virus) antibody and preparation method and application thereof

The invention relates to an antibody used for treatment of diseases, in particular to cervical cancer, related to human papilloma virus infection, and a preparation method and an application thereof.
Owner:SHANGHAI ZERUN BIOTECHNOLOGY CO LTD

Synthetic virus-like particles with heterologous epitopes

The invention is a series of synthetic virus-like particles comprising a heterologous conformational epitope useful in the characterization of human papillomavirus infection, and useful to vaccinate individual for protection against HPV 6 and HPV 11 infections, and assays employing the synthetic virus-like particles.
Owner:MERCK SHARP & DOHME CORP

Compositions and methods for treating skin ailments

Compositions that comprise a polymer entrapping an oxidizing agent are disclosed. The disclosed compositions are used in the treatment of skin ailments such as human papilloma virus infections.
Owner:DEGANIA SILICON

Immunogenic HPV L2-Containing VLPs and Related Compositions, Constructs, and Therapeutic Methods

The invention provides immunotherapeutic and prophylactic bacteriophage viral-like particle (VLPs) which are useful in the treatment and prevention of human papillomavirus (HPV) infections and related disorders, including cervical cancer and persistent infections associated with HPV. Related compositions (e.g. vaccines), nucleic acid constructs, and therapeutic methods are also provided. VLPs and related compositions of the invention induce high titer antibody responses against HPV L2 and protect against HPV challenge in vivo. VLPs, VLP-containing compositions, and therapeutic methods of the invention induce an immunogenic response against HPV infection, confer immunity against HPV infection, protect against HPV infection, and reduce the likelihood of infection by HPV infection.
Owner:STC UNM

Kit for fluorescent PCR (Polymerase Chain Reaction) detection of high-risk HPV (Human Papilloma Virus)

The invention provides a kit for fluorescent PCR (Polymerase Chain Reaction) detection of a high-risk HPV (Human Papilloma Virus). The kit comprises a nucleic acid releasing agent and a PCR reaction solution, wherein the nucleic acid releasing agent comprises 0.01-05mmol / L surfactin, 20-300mmol / L potassium chloride, 0.01-2% sodium dodecyl sulfate and 0.05-1% ethanol; the PCR reaction solution comprises high-risk HPV16-type and 18-type primer probe sequences and internal standard primer probe sequences. The invention aims at providing a kit for fluorescent quantitative PCR detection of high-risk Human Papilloma Virus, and the kit has the advantages of fastness in operation, simple method, high detection sensitivity and wide detection range. By virtue of the kit, a common fast fluorescent PCR detection is carried out on DNA nucleic acid fragments of the high-risk human papilloma virus in unknown samples, such as cast-off cells of the surface of a verruca acuminata body, women cervical epithelial cells and genital secretion and the detection results can be applied in the auxiliary diagnosis of the high-risk human papilloma virus infection and the early screening of cervical cancer.
Owner:SANSURE BIOTECH INC

HPV (human papilloma virus) high-risk typing fluorescence PCR (polymerase chain reaction) detection kit

The invention provides an HPV (human papilloma virus) high-risk typing fluorescence PCR (polymerase chain reaction) detection kit which comprises a nucleic acid releaser and two or more PCR reaction solutions, wherein the nucleic acid releaser comprises 0.01-0.5 mmol / L surfactin, 20-300 mmol / L potassium chloride, 0.01-2% of sodium dodecylsulfate and 0.05-1% of ethanol. One of the PCR reaction solutions comprises high-risk HPV 16 type and / or 18 type primer probe sequences, and another PCR reaction solution comprises an internal reference primer probe sequence. The kit provided by can be used for carrying out quick fluorescence PCR typing detection on DNA (deoxyribonucleic acid) nucleic acid segments of high-risk HPV in wart surface shedding cells, female cervix epithelial cells, genital secretion and other unknown samples; and the detection result can be used for auxiliary diagnosis of high-risk HPV infection, early screening of cervical carcinoma, follow-up survey of cervix pathological changes and instruction of vaccine development.
Owner:SANSURE BIOTECH INC

Traditional Chinese medicine composition used for treating human papillomavirus infection as well as preparation method and application thereof

The invention provides a traditional Chinese medicine composition used for treating human papillomavirus infection. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 8-12 parts of rhizoma atractylodis stir-fried with bran, 8-12 parts of white atractylodes rhizome stir-fried with bran, 8-12 parts of golen cypress, 20-40 parts of coix seed, 8-12 parts of paris polyphylla, 8-12 parts of isatis root, 20-40 parts of oldenlandia diffusa and 8-12 parts of rhizoma smilacis glabrae; and the aim of treating human papillomavirus infection is achieved by tonifying spleen, benefiting qi, promoting diuresis, clearing heat and detoxifying. The invention also provides a preparation method and an application of the traditional Chinese medicine composition.
Owner:南京融昱医药产业有限公司

Method of immunotherapy for treament of human papillomavirus infection

A method of treating human papillomavirus (HPV), by administering a therapeutically effective amount of a primary cell-derived biologic to a patient infected with HPV, and inducing an immune response to HPV. A method of overcoming HPV-induced immune suppression of Langerhans cells (LC), by administering a therapeutically effective amount of a primary cell-derived biologic to a patient infected with HPV, and activating LC. A method of increasing LC migration towards lymph nodes, by administering a therapeutically effective amount of a primary cell-derived biologic to a patient infected with HPV, activating LC, and inducing LC migration towards lymph nodes. A method of generating immunity against HPV, by administering an effective amount of a primary cell derived biologic to a patient infected with HPV, generating immunity against HPV, and preventing new lesions from developing.
Owner:BROOKLYN IMMUNOTHERAPEUTICS LLC

HPV vaccines

Provided herein are genetically modified arenaviruses suitable as vaccines against neoplastic diseases or cancer. The invention also relates to pharmaceutical compositions and methods for the prevention or treatment of certain infections causing neoplastic diseases or cancer, such as infections with oncogenic viruses. Specifically, provided herein are pharmaceutical compositions, vaccines, and methods of preventing or treating diseases and conditions caused by and associated with infections with Human Papillomavirus (HPV), such as cervical cancer, anogenital cancer, head and neck cancer and skin cancers. Also provided herein are immunotherapies for the treatment of a neoplastic disease, such as a neoplastic disease caused by infection with oncogenic viruses.
Owner:HOOKIPA BIOTECH GMBH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products